SOLIGENIX 2 RSS Feed | Nachrichten - www.finanzen.netwww.finanzen.net bietet Finanznachrichten zum weltweiten BörsengeschehenFinanzenhttps://www.finanzen.netde-definanzen.net GmbHSun, 05 Apr 2026 21:18:48 +0200https://images.finanzen.net/images/finanzen_net_neu.gifSOLIGENIX 2 RSS Feed | Nachrichten - www.finanzen.nethttps://www.finanzen.netPositive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford)Thu, 18 Dec 2025 13:30:00 +0100https://www.finanzen.net/nachricht/aktien/positive-clinical-results-from-phase-2-trial-of-sgx945-for-the-treatment-of-behçet-s-disease-published-in-rheumatology-oxford-15367979
  • Study results support advancing SGX945 in this difficult-to-treat orphan disease
  • Results suggest potential durability of response for maintenance therapy

]]>https://www.finanzen.net/nachricht/aktien/positive-clinical-results-from-phase-2-trial-of-sgx945-for-the-treatment-of-behçet-s-disease-published-in-rheumatology-oxford-15367979Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate PsoriasisWed, 17 Dec 2025 13:30:00 +0100https://www.finanzen.net/nachricht/aktien/soligenix-announces-top-line-results-of-the-phase-2a-study-of-sgx302-synthetic-hypericin-in-patients-with-mild-to-moderate-psoriasis-15364814

Optimized Gel Formulation Demonstrates Clinical Success in Third Cohort of Patients

PRINCETON, ...

]]>https://www.finanzen.net/nachricht/aktien/soligenix-announces-top-line-results-of-the-phase-2a-study-of-sgx302-synthetic-hypericin-in-patients-with-mild-to-moderate-psoriasis-15364814Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell LymphomaWed, 19 Nov 2025 13:30:00 +0100https://www.finanzen.net/nachricht/aktien/soligenix-achieves-enrollment-milestone-for-planned-interim-analysis-in-confirmatory-phase-3-clinical-trial-of-hybryte-for-the-treatment-of-cutaneous-t-cell-lymphoma-15291556
  •  50 of 80 patients enrolled in FLASH2 study

  •  Blinded Response Rate to Date Exceeds Trial Estimate

]]>https://www.finanzen.net/nachricht/aktien/soligenix-achieves-enrollment-milestone-for-planned-interim-analysis-in-confirmatory-phase-3-clinical-trial-of-hybryte-for-the-treatment-of-cutaneous-t-cell-lymphoma-15291556Soligenix Announces Recent Accomplishments and Third Quarter 2025 Financial ResultsFri, 07 Nov 2025 13:30:00 +0100https://www.finanzen.net/nachricht/aktien/soligenix-announces-recent-accomplishments-and-third-quarter-2025-financial-results-15219755

PRINCETON, N.J., Nov. 7, 2025 /PRNewswire/ -- ]]>https://www.finanzen.net/nachricht/aktien/soligenix-announces-recent-accomplishments-and-third-quarter-2025-financial-results-15219755Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell LymphomaTue, 14 Oct 2025 13:30:00 +0200https://www.finanzen.net/nachricht/aktien/soligenix-updates-united-states-medical-advisory-board-for-cutaneous-t-cell-lymphoma-15044328

Providing Strategic Medical Guidance in Advancing HyBryte™ Clinical Development

PRINCETON, ...

]]>https://www.finanzen.net/nachricht/aktien/soligenix-updates-united-states-medical-advisory-board-for-cutaneous-t-cell-lymphoma-15044328Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell LymphomaTue, 07 Oct 2025 13:30:00 +0200https://www.finanzen.net/nachricht/aktien/soligenix-achieves-important-safety-milestone-in-its-confirmatory-phase-3-clinical-trial-of-hybryte-for-the-treatment-of-cutaneous-t-cell-lymphoma-14961269

FLASH2 Study Interim Efficacy Analysis Targeted for 1H2026

Enrollment Update Remains on Track ...

]]>https://www.finanzen.net/nachricht/aktien/soligenix-achieves-important-safety-milestone-in-its-confirmatory-phase-3-clinical-trial-of-hybryte-for-the-treatment-of-cutaneous-t-cell-lymphoma-14961269